Leerink Swann started coverage on shares of Clovis Oncology (NASDAQ:CLVS) in a report released on Monday, The Fly reports. The firm issued a market perform rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Clovis Oncology from a sell rating to a strong sell rating in a research note on Friday, June 8th. JPMorgan Chase & Co. reiterated a buy rating and set a $71.00 target price on shares of Clovis Oncology in a research note on Friday. ValuEngine upgraded shares of Clovis Oncology from a strong sell rating to a sell rating in a research note on Friday, June 1st. Zacks Investment Research downgraded shares of Clovis Oncology from a hold rating to a sell rating in a research note on Tuesday, July 10th. Finally, Gabelli reiterated a buy rating on shares of Clovis Oncology in a research note on Monday, July 16th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $78.87.

NASDAQ CLVS opened at $32.64 on Monday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 9.21 and a current ratio of 10.03. Clovis Oncology has a 1 year low of $31.19 and a 1 year high of $86.26.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.38) by ($0.56). Clovis Oncology had a negative net margin of 382.83% and a negative return on equity of 94.28%. The company had revenue of $23.76 million during the quarter, compared to analyst estimates of $22.44 million. During the same quarter in the prior year, the company earned ($1.29) EPS. The business’s revenue was up 62.5% on a year-over-year basis. sell-side analysts predict that Clovis Oncology will post -6.77 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in CLVS. Redmile Group LLC acquired a new stake in shares of Clovis Oncology during the second quarter worth about $79,964,000. Palo Alto Investors LP raised its holdings in Clovis Oncology by 16.2% during the first quarter. Palo Alto Investors LP now owns 3,955,660 shares of the biopharmaceutical company’s stock worth $208,859,000 after purchasing an additional 552,879 shares in the last quarter. Summit Trail Advisors LLC raised its holdings in Clovis Oncology by 4,092.7% during the first quarter. Summit Trail Advisors LLC now owns 249,258 shares of the biopharmaceutical company’s stock worth $249,000 after purchasing an additional 243,313 shares in the last quarter. Carmignac Gestion raised its holdings in Clovis Oncology by 14.3% during the first quarter. Carmignac Gestion now owns 1,509,540 shares of the biopharmaceutical company’s stock worth $79,704,000 after purchasing an additional 188,676 shares in the last quarter. Finally, Emerald Advisers Inc. PA raised its holdings in Clovis Oncology by 71.6% during the second quarter. Emerald Advisers Inc. PA now owns 355,033 shares of the biopharmaceutical company’s stock worth $16,143,000 after purchasing an additional 148,107 shares in the last quarter.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Read More: Dividend Stocks – Are They Right For You?

The Fly

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.